Previous 10 | Next 10 |
The markets have been performing very well in 2019 with the Dow Jones, the Nasdaq, and the S&P 500 all up more than 20% since the beginning of the year. That's great news for investors who are already holding stocks, but for those looking to get into the market for the first time, it means c...
Exelixis (NASDAQ: EXEL ) inks an agreement with Roche ( OTCQX:RHHBY ) aimed at evaluating the combination of Cabometyx (cabozantinib) and Tecentriq (atezolizumab) for the treatment of patients with locally advanced or metastatic solid tumors. More news on: Exelixis, Inc., Roche Hold...
– New pivotal trials will evaluate the combination of cabozantinib and atezolizumab in patients with advanced non-small cell lung cancer, castration-resistant prostate cancer and renal cell carcinoma – – Collaboration based on data from phase 1b COSMIC-021 tri...
"If tragedy never entered our lives, we wouldn't appreciate the magic ." - Nikki Rowe I have had a few questions around mid-cap oncology concern Exelixis ( EXEL ) recently as the shares got a boost from the buyout of ArQule ( ARQL ) to start the week. A full investment analysis is...
Exelixis (NASDAQ: EXEL ) announces positive results from IMspire150, the Phase 3 trial of atezolizumab (TECENTRIQ), cobimetinib (COTELLIC) and vemurafenib (ZELBORAF) in people with previously untreated BRAF V600 mutation-positive advanced melanoma. More news on: Exelixis, Inc., Roche Hol...
Exelixis, Inc. (Nasdaq: EXEL) today announced positive results from IMspire150, the phase 3 trial of atezolizumab (TECENTRIQ ® ), cobimetinib (COTELLIC ® ) and vemurafenib (ZELBORAF ® ) in people with previously untreated BRAF V600 mutation-positive advanced melanoma. Genentech...
Merck's $2.7B bid for ArQule is yet another example of the Big Biopharma's high regard for oral kinase inhibitors for treating cancer. ArQule's lead drug is ARQ 531, an oral inhibitor of Bruton's tyrosine kinase (BTK). More news on: Pfizer Inc., Eli Lilly and Company, AbbVie Inc., Health...
Exelixis, Inc. (EXEL) Piper Jaffray 31st Annual Healthcare Brokers Conference December 3, 2019 10:00 am ET Corporate Participants Chris Senner - Chief Financial Officer Andrew Peters - Vice President, Strategy Conference Call Participants Ted Tenthoff - Piper Jaffray Prese...
Buying growth stocks in December is generally a good idea. Because of the so-called " January effect ," growth stocks -- especially those in the small- to mid-cap realm -- tend to enjoy a nice bump early in the new year. Which growth stocks should investors have on their radar heading int...
– Presentations to be webcast on www.exelixis.com – Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis’ management team will provide an overview of the company at the following investor conferences in December: Evercore ISI 2 nd Annual ...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...